MYNZ

Mainz Biomed N.V.

1.07 USD

Last updated Nov 28, 19:39 UTC

Yesterday HIGH

$1.15

Yesterday LOW

$1.06

52w HIGH

$9.12

52w LOW

$1.05

EPS

-0.39

PE

-2.74

Next Earnings

Sep 6, 2023

Overview News Government Trades

Mainz Biomed N.V. stock is down -48.31% since 30 days ago. The next earnings date is Sep 6, 2023. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 2 November’s closed higher than October. 50% of analysts rate it a buy.

Mainz Biomed B.V. develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. The company was founded in 2008 and is based in Mainz, Germany.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

mainzbiomed.com

Upwallstreet

Tue Oct 10, 2023

Big Pharma Could Transform Into BioTech Pharma

As the word itself says, biotechnology is simply technology based on biology. It uses the knowledge of cellular and biomolecular processes to develop technologies that improve our lives and overall health of the planet that is only our home.
Benzinga Insights

Tue Oct 10, 2023

Stocks That Hit 52-Week Lows On Tuesday

Tuesday saw 132 companies set new 52-week lows.
Upwallstreet

Wed Oct 4, 2023

Mainz Biomed Continues To Transform Early Cancer Detection Across The Globe

While Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) are making great progress in cancer treatments, the importance of early detection in combating this disease cannot be overstated.
Benzinga Newsdesk

Wed Oct 4, 2023

Mainz Biomed Announces Live Launch of ColoAlert With Bioclinica in Romania
Benzinga Insights

Mon Oct 2, 2023

Stocks That Hit 52-Week Lows On Monday

On Monday, 369 companies set new 52-week lows.
Upwallstreet

Wed Sep 27, 2023

Mainz Biomed To Present The Power Of mRNA That Promises To Revolutionize Medicine

Pharma companies across the globe, including Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA), are harnessing the potential of mRNA which is creating plenty of space for scientific improvement in the fight against pathogens.
Benzinga Insights

Tue Sep 26, 2023

What 5 Analyst Ratings Have To Say About Mainz Biomed
Benzinga Newsdesk

Tue Sep 26, 2023

Cantor Fitzgerald Reiterates Overweight on Mainz Biomed, Maintains $9 Price Target

Cantor Fitzgerald analyst Ross Osborn reiterates Mainz Biomed (NASDAQ:MYNZ) with a Overweight and maintains $9 price target.
Benzinga Newsdesk

Fri Sep 22, 2023

HC Wainwright & Co. Maintains Buy on Mainz Biomed, Raises Price Target to $9

HC Wainwright & Co. analyst Yi Chen maintains Mainz Biomed (NASDAQ:MYNZ) with a Buy and raises the price target from $7 to $9.
Upwallstreet

Fri Sep 22, 2023

AI To Revolutionize Clinical Trials And Diagnostics

With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving diagnostics.